OR WAIT null SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Intranasal vaccines are showing promise, but there are multiple formulation hurdles to overcome.
The delivery platform depends on API-related factors, and the development stage of the product.
October 22, 2021
EMA's CHMP has approved two new manufacturing sites and a ready-to-use formulation of Comirnaty.
EMA has started its evaluation of further expanded use of Comirnaty in children aged between five years and 11 years old.
October 15, 2021
In this collaboration, Takeda will utilize Poseida's biodegradable DNA and RNA nanoparticle delivery technology and other proprietary genetic engineering platforms for the research and development of gene therapies.
October 03, 2021
Conventional and robotic automation inside closed systems reduces risk.
Evolving equipment designs meet the unique needs of continuous processing techniques.
September 29, 2021
Alternatives to animal testing and in-vivo assays are occurring as a result of recent scientific advances.
September 23, 2021
In an amendment to their existing contract manufacturing agreement, Celsian and Poly Pharm expand GEN-1 program collaboration to add clinical and commercial batches of investigational vaccine.
New data finds J&J COVID-19 vaccine and booster to provide increased protection against COVID-19.
September 16, 2021
Considering interactions and understanding regulatory requirements are crucial when developing a drug or biologic product for use with a medical device.
September 13, 2021
When designing and manufacturing a pMDI or DPI combination drug-delivery device, the commercial stage should be kept in mind from the beginning of development.